ICER calls out three drugs from BMS and Lilly in report on unsupported price increases in California – Endpoints News

Drug pric­ing watch­dog ICER on Thurs­day re­leased its fi­nal re­port on drug price in­creas­es in Cal­i­for­nia that were un­sup­port­ed by new clin­i­cal ev­i­dence, point­ing to three out­liers — Bris­tol My­ers Squibb’s can­cer drugs Revlim­id and Spry­cel, and Eli Lil­ly’s mi­graine drug Em­gal­i­ty.
The re­port builds on a price trans­paren­cy law passed in Cal­i­for­nia in 2017, which re­quires man­u­fac­tur­ers to re­port year-over-year spend­ing in­creas­es to pre­scrip­tion drugs’ WAC prices, but does not in­clude net prices, which ICER took is­sue with.
The non­prof­it watch­dog said it win­nowed down lists of the most ex­pen­sive drugs in Cal­i­for­nia from 2020, seek­ing in­put as to whether its fig­ures on net prices, if avail­able, were cor­rect. While con­ver­sa­tions with man­u­fac­tur­ers on net prices can­celed out many of the top ones list­ed, ICER said in all three of these cas­es, the price in­creas­es were high and un­jus­ti­fied by new clin­i­cal ev­i­dence.
In the case of BMS’ Revlim­id (lenalido­mide), which be­gan fac­ing gener­ic com­pe­ti­tion this year, ICER said it was ranked 14th on Cal­i­for­nia’s 2020 list of spe­cial­ty drugs with the high­est year-over-year in­creas­es in to­tal spend­ing, with the WAC in­creas­ing by about 6% in 2020, al­though the net price in­crease was un­known.
BMS’ Spry­cel (dasa­tinib) sim­i­lar­ly saw a 6% WAC price spike in 2020, un­sup­port­ed by new da­ta, and ICER said its change in net price in 2020 amount­ed to about 10%.
More in­creas­es may have oc­curred in the in­ter­ven­ing years too as In­dia-based gener­ic man­u­fac­tur­er Apo­tex set­tled with BMS in 2013 and agreed to not launch its gener­ic ver­sion of Spry­cel un­til Sept. 2024.
In the case of Lil­ly’s Em­gal­i­ty (gal­canezum­ab), which the com­pa­ny says is pro­tect­ed from gener­ics with patents through 2033, the WAC in­creased by about 5%. The net price in­crease in the same pe­ri­od for Em­gal­i­ty re­mains un­known, ICER said, not­ing that SSR Health con­sid­ered its es­ti­mates of change in net price over the same 12-month pe­ri­od to be po­ten­tial­ly not re­li­able and the man­u­fac­tur­er did not pro­vide new in­fo.
All in all, ICER, which re­ceived fund­ing from the Cal­i­for­nia Health­Care Foun­da­tion to pro­duce this re­port, called on states to en­sure net price in­fo is in­clud­ed in any fu­ture drug price trans­paren­cy laws.
“States seek­ing to iden­ti­fy drugs for which in­creas­es in spend­ing may be in­ap­pro­pri­ate should in­cor­po­rate a re­quire­ment for re­port­ing of net price in­creas­es at the state lev­el across all pay­ers,” the re­port con­cludes.
Key takeaways:
The data supporting regulatory approval alone are often insufficient for demonstrating the added benefit of a new therapy
Planning in advance to continuously deliver data that illustrate value and post-launch, to not only the regulator, but payers, healthcare professionals, and patients results in more clinically meaningful benefits
By working cross-functionally, biopharmaceutical teams can uncover evidence gaps and better shape registration trials to ensure the needs of as many stakeholders as possible are met
Revance feels like it has a competitive advantage over AbbVie’s blockbuster Botox with only biannual injections of its freshly approved Daxxify, as opposed injections every three or four months that Botox requires. But you come at the king, you best not miss, and to bolster the executive team Revance has now tapped David Hollander as CMO. Hollander was previously the chief R&D officer at Aerie Pharmaceuticals, which was sold to Alcon a couple months ago in a $770 million deal, and he has familiarity with the Botox developer through his 10 years at Allergan. From 2011-16, he was Allergan’s VP, global therapeutic area head in clinical development for anterior segment and consumer eye care.
After two Florida-based CRO study coordinators pled guilty to falsifying clinical trial data, the DOJ said Wednesday that those two have been sentenced to more than two years in prison each.
Federal judge Donald Graham sentenced Analay Rico, lead study coordinator at Tellus Clinical Research, to 40 months in prison, and Daylen Diaz, assistant study coordinator and research assistant at Tellus, to 24 months in prison, along with $2.1 million in fines related to their conspiracy to commit fraud.
Back in 2017, Takeda shelled out more than $5 billion for a smaller company called Ariad Pharmaceuticals, its leukemia drug Iclusig (ponatinib) and its ALK-inhibiting lung cancer drug Alunbrig (brigatinib).
Fast forward five years, and while Iclusig continues to pull in more than $200 million per year for Takeda, the company is now looking to fend off generic competitors, filing suit in New Jersey federal court earlier this week to block a competitor, Canada-based Apotex.
Speaking in a Starbucks booth on the sidelines of ASCO in June, Kenneth Galbraith emphasized he wanted what Daiichi Sankyo got for its HER2 breakout drug: a Big Pharma partner that could turn its bispecific into a worldwide med.
While not quite the size of an AstraZeneca, Galbraith’s Zymeworks has lined up a second partner for its HER2 bispecific antibody, known as zanidatamab. In comes neuroscience and oncology drugmaker Jazz Pharmaceuticals, itself eyeing up to $3.7 billion in revenue this year, who will be doling out an initial $50 million to nab the development and commercialization rights for all indications of the late-stage asset in most markets.
Unlock this story instantly and join 151,700+ biopharma pros reading Endpoints daily — and it’s free.
Indegene is building out its life sciences’ marketing business again — this time acquiring a pharma marketing agency.
CultHealth is its first ad agency buy, although Indegene has been “providing advertising and marketing services to life sciences companies for many years,” said Nancy Phelan, senior VP at Indegene and a former pharma commercial leader at both Pfizer and Bristol Myers Squibb.
Unlock this story instantly and join 151,700+ biopharma pros reading Endpoints daily — and it’s free.
The Medicines Patent Pool on Thursday unveiled a new voluntary licensing agreement with Novartis to increase access to its patented, second-line chronic myeloid leukemia drug Tasigna (nilotinib) in certain lower-income countries.
The drug, which is on the WHO’s list of essential medicines, will now be made by select generic manufacturers and offered in seven middle-income countries — Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines and Tunisia — where patents on the product are pending or in force.
Unlock this story instantly and join 151,700+ biopharma pros reading Endpoints daily — and it’s free.
Behind Amgen and Mirati are a whole host of players lining up their own KRAS candidates.
Roche is no exception. The Big Pharma already has its own in-house KRAS drug from its subsidiary Genentech that is currently in Phase I studies, but is now expanding its options.
Roche has licensed a preclinical KRAS program from Hookipa Pharma for $25 million upfront, Hookipa announced Thursday morning. Roche also has the option of adding a second immunotherapy candidate for $15 million.
Unlock this story instantly and join 151,700+ biopharma pros reading Endpoints daily — and it’s free.
Less than 2 years after some Oxford grads pieced together a little £6 million seed fund to launch their discovery outfit, the antibody developer has been scooped up by one of the pharma giants scouting the bargain aisle of early-stage drug development.
And the founders did considerably better than the seed round might suggest.
AbbVie is swooping in for the buyout with $255 million in cash for DJS Antibodies, plus some unspecified milestones that could range quite high, given the preclinical nature of the GPCR work involved.
Unlock this story instantly and join 151,700+ biopharma pros reading Endpoints daily — and it’s free.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.


Add a Comment

Your email address will not be published. Required fields are marked *